Agency for Healthcare Research and Quality (AHRQ, formerly AHCPR). Depression Guideline Panel. Depression in primary care: volume 1. Detection and diagnosis. Clinical practice guideline, number 5. AHCPR Publication No. 93-0550. Rockville, MD, Agency for Health Care Policy and Research, 1993.
Alzheimer’s Association. Leteprinim potassium (Neotrofin®) for treating Alzheimer’s. www.alz.org/research/clintrials/neotrofin.htm. Accessed on June 25, 2002.
Alzheimer Research Forum. Drugs in clinical trials. www.alzforum.org. Accessed on July 2, 2002.
American Cancer Society. Cancer facts & figures 2002. Atlanta, GA. American Cancer Society, 2002.
American Cancer Society. Cancer vaccines show continuing improvement. May 16, 2001. www.cancer.org. Accessed on June 25, 2002.
American Heart Association. 2002 heart and stroke statistical update. Dallas, TX, American Heart Association. 2001.
Andersson KE, Chapple CR, Hofner K. Future drugs for the treatment of benign prostatic hyperplasia. World Journal of Urology. 19(6), 436-442, 2002.
Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Annals of Medicine. 32(3), 164-76, 2000.
Birkett D, Mitchell A, and McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Affairs. 20(3), 104-114, 2001.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine. 343(21), 1520-1528, November 2000.
Boskey AL. Musculoskeletal disorders and orthopedic conditions. Journal of the American Medical Association. 285(5), 619-623, 2001.
British National Formulary (BNF). www.bnf.org. Accessed July 9, 2002.
Bumol TF, Watanabe AM. Genetic information, genomic technologies, and the future of drug discovery. Journal of the American Medical Association. 285(5), 551-555, 2001.
Burt C. National trends in the use of medications in office-based practice, 1985-1999. Health Affairs. 21(4), 206-214, July/August 2002.
Calfee, J.E. The unintended consequences of price controls. American Enterprise Institute website. www.aei.org/ra/racalfee3.htm. Accessed July 1, 2002.
Centers for Disease Control and Prevention. Healthy aging: preventing disease and improving quality of life among older Americans. www.cdc.gov/nccdphp/aag-aging.htm. Accessed on June 24, 2002.
Centers for Disease Control and Prevention. Morbidity and mortality weekly report: surveillance for asthma—United States, 1980-1999. March 29, 2002.
Centers for Disease Control and Prevention, National Center for Health Statistics. Trends in causes of death among the elderly. Aging Trends No.1. Atlanta, GA, March 2001.
Center for Disease Control and Prevention, National Center for Health Statistics. New asthma estimates: tracking prevalence, health care, and mortality. October 5, 2001. www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm. Accessed on July 1, 2002.
Center for Disease Control and Prevention, National Center for Health Statistics. Summary health statistics for U.S. Adults: National Health Interview Survey, 1997. CDC, Department of Health and Human Services. May 2002.
Centers for Disease Control and Prevention. Preventing heart disease and stroke: addressing the nation’s leading killers. www.cdc.gov/nccdphp/cvdaag.htm. Accessed on June 24, 2002.
Centers for Disease Control and Prevention. Arthritis: the nation’s leading cause of disability. www.cdc.gov/nccdphp/arthritis. Accessed on June 24, 2002.
Centers for Disease Control and Prevention. Diabetes: disabling, deadly, and on the rise. www.cdc.gov/diabetes/pubs/glance.htm. Accessed on June 24, 2002.
Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. Preventing the diseases of aging. Chronic Disease Notes & Reports. 12(3),1999.
Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 359, 2072-2077, 2002.
Crystal RG. Research opportunities and advances in lung disease. Journal of the American Medical Association. 285(5), 612-618, 2001.
Cutler DM, McClellan M. Is technological change in medicine worth it? The Value of Rx Innovation: A Primer. Health Affairs. Pages 1-19, 2001.
Davidson, S. Quicker drug approvals on the way for Europe. Nature Biotechnology. Nature Publishing Group. 10, 798-799, September 2001.
de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105(18), 2159-65, 2002.
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 346(6), 393-403, 2002.
Dykes, L. Why price controls are the wrong prescription. Pacific Research Institute. June 13, 2001. www.pacificresearch.org/pub/act/2001/act_01-06-13a.html. Accessed July 1, 2002.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Journal of the American Medical Association. 282(22), 2124, 1999.
Europe Economics. Access to important new medicines: where and why do patients wait? Europe Economics. London, UK. 2000.
European Commission. High level group on innovation and provision of medicines: recommendations for action. European Communities. Brussels, Belgium. May 7, 2002.
Evenson B. Health Canada finally approves lymphoma drug: Rituxan an effective anti-cancer agent with few side-effects. National Post. April 5, 2000.
Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology. 50(4), 883, 1998.
Federal Interagency Forum on Aging-Related Statistics. Older Americans 2000: key indicators of well-being. Federal Interagency Forum on Aging-Related Statistics. Washington, DC, US Government Printing Office, 2000.
Freedman VA, Aykan H, Martin, LG. Another look at aggregate changes in severe cognitive impairment. Journal of Gerontology. Series B, Psychological Sciences and Social Sciences. 56(2), S100-11, 2002.
Freedman VA, Martin, LG. Contribution of chronic conditions to aggregate changes in old-age functioning. American Journal of Public Health. 90(11), 1755-60, 2000.
Freedman VA, Martin, LG. Understanding trends in functional limitations among older Americans. American Journal of Public Health. 88(10), 1457-62, 1998.
Fuhrmans V, Naik G. In Europe, drug makers fight against mandatory price cuts. The Wall Street Journal. June 7, 2002.
Gambardella A, Orsenigo L, Pammolli F. Global competativeness in pharmaceuticals, a European perspective. Report prepared for Enterprise Directorate-General of the European Commission. European Communities. 2001.
Gawchik SM, Saccar CL. Role of antileukotriene agents in asthma therapy. Journal of the American Osteopathic Association. 100(1), 32, 37-43, January 2000.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. New England Journal of Medicine. 346(4), 257-268, 2002.
Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with Angiotensin-converting enzyme inhibitors. Annals of Internal Medicine. 131(9), 660-667, 1999.
Hansel TT, Barnes PJ. Novel drugs for treating asthma. Current Allergy and Asthma Reports. 1(2), 164-173, 2001.
Hawkes N. Patients are denied life-saving cancer drug. London Times. May 28, 2002.
Health Canada Online. Drug product database. www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/dpd.html. Accessed on July 9, 2002.
Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. National Vital Statistics Report, 47(19). DHHS Publication No. 99-1120. Hyattsville, MD: National Center for Health Statistics, 1999.
Koopman WJ. Prospects for autoimmune disease: research advances in rheumatoid arthritis. Journal of the American Medical Association . 285(5), 648-650, 2001.
Kremer, M. Creating markets for new vaccines part II: design issues. NBER working paper 7717. National Bureau of Economic Research. Cambridge, MA. May 2000.
Kshirsagar AV, Joy MS, Hogan SL, et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. American Journal of Kidney Disease. 35(4), 297-307, 2000.
Lawrence, F. The battle over immunization. The Guardian. London, U.K. www.guardian.co.uk/medicalscience/story/0,1129,541949,00.html. Accessed July 2, 2002.
Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. Journal of the American Medical Association. 285(5), 581-587, 2001.
Leitersdorf E. Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. International Journal of Clinical Practice. 56(2), 116-119, March 2002.
Lewin Group. The impact of the Canadian system on access to new medical technology including prescription drugs. The Lewin Group. March 7, 2000.
Lichtenberg FR, Are the benefits of newer drugs worth their costs? Evidence from the 1996 MEPS. The Value of Rx Innovation: A Primer. Health Affairs, pages 21-31. 2001.
Lipworth BJ. Leukotriene-receptor antagonists. Lancet. 353(9146), 57-62, 1999.
Livingston DM, Shivdasani R. Toward mechanism-based cancer care. Journal of the American Medical Association . 285(5), 588-593, 2001.
Margolin K. Inhibition of vascular endothelial growth factor in the treatment of solid tumors. Current Oncology Reports. 4(1), 20-8, 2001.
McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. New England Journal of Medicine. 344(5), 333-340, 2001.
Merck & Co. E-mail communication to the Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services. June 28, 2002.
Mulrow CD, Williams JW Jr., Trivedi M, et al. Evidence report on treatment of depression-newer pharmacotherapies. Psychopharmacology Bulletin. 34(4), 409-795, 1998.
Murray CJL, Lopez AD, eds. Summary: the global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA; published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press, 1996.
Narrow WE. One-year prevalence of depressive disorders among adults 18 and over in the U.S.: NIMH ECA prospective data. Population estimates based on U.S. Census estimated residential population age 18 and over on July 1, 1998. Unpublished. Accessed on June 24, 2002. www.nimh.nih.gov/pubicat/elderydepsuicide.cfm.
National Institute for Clinical Excellence. (NICE) Press releases. www.nice.org.uk. Accessed on July 9, 2002.
National Institutes of Health. Medications under development for the treatment of seniors. E-mail communication. June 27, 2002.
National Institutes of Health. New agents in development. E-mail communication. July 2, 2002.
National Institutes of Health, National Library of Medicine. Cholesterol. Medline Plus Health Information Database. www.nih.nlm/medlineplus/ Accessed on June 24, 2002.
National Institutes of Health, National Heart, Lung and Blood Institute. Cholesterol Lowering Medicines. rover.nhlbi.nih.gov/chd/meds.htm Accessed on June 24, 2002.
National Institutes of Health, National Cancer Institute. Annual report shows overall decline in U.S. cancer death rates; cancer burden is expected to rise with an aging population. May 14, 2002. newscenter.cancer.gov/pressreleases/2002reportnation.html. Accessed June 24, 2002.
National Institutes of Health, NIDDK. Prostatic enlargement: benign prostatic hyperplasia. www.niddk.nih.gov/health/urolog/pubs/prostate/index.htm. Accessed on July 1, 2002.
National Institutes of Health, National Institute of Neurological Disorders and Stroke. Headache—hope through research. www.ninds.nih.gov/health_and_medical/pubs/headache_htr.htm?format=printable. Accessed July 1, 2002.
National Institutes of Health, National Institute of Neurological Disorders and Stroke. Migraine update. www.ninds.nih.gov/health_and_medical/pubs/migraineupdate.htm?format=printable. Accessed July 1, 2002.
National Institutes of Health, National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine. 333(24), 1581-1587, 1995.
National Institutes of Health, National Library of Medicine. Diabetes mellitus, non-insulin-dependent. www.clinicaltrials.gov. Accessed on June 25, 2002.
National Institutes of Health. Osteoporosis and Related Bone Diseases, National Resource Center. Osteoporosis overview. www.osteo.org/osteo.html. Accessed on June 24, 2002.
National Institutes of Health, National Library of Medicine, National Institute of Diabetes and Digestive and Kidney Disease. Clinical alert: diet and exercise dramatically delay type 2 diabetes; diabetes medication metformin also effective. August 8, 2001. www.nlm.nih.gov/databases/alerts/diabetes01.html. Accessed on June 24, 2002.
National Osteoporosis Foundation. Patient Info: medications and osteoporosis. www.nof.org/patientinfo/medications.htm. Accessed on June 24, 2002.
Neumann PJ, Sandberg EI, Bell CM, et al. Are pharmaceuticals cost effective? A review of the evidence. Health Affairs. 19(2),92-109, 2001.
New Zealand Guidelines Group. Guidelines for the support and management of people with dementia: cognition of enhancing drug treatments in dementia. Enigma Publishing Limited. 2002. www.nzgg.org.nz/library/gl_complete/dementia/treatment.cfm. Accessed July 9, 2002.
Olefsky JM. Prospects for research in diabetes mellitus. Journal of the American Medical Association. 285(5), 628-632, 2001.
Ontario Ministry of Health and Long Term Care. Ontario drug benefit formulary, number 37. March 7, 2001. www.gov.on.ca/health/english/program/drugs/obdf_mn.html. Accessed on July 9, 2002.
Pacher P, Kohogyi E, Kecskemeti V, et al. Current trends in the development of new antidepressants. Current Medicinal Chemistry. 8,89-100, 2001.
Paget SA. Efficacy of anakinra in bone: comparison to other biologics. Advances in Therapy. 19(1), 27-39, 2002.
Parving HH, Hovind P, Rossing K, et al. Evolving strategies for renoprotection: diabetic nephropathy. Current Opinion Nephrology and Hypertension. 10(4), 515-522, 2001.
Pharmaceutical Management Agency (PHARMAC). New Zealand pharmaceutical schedule. www.pharmac.govt.nz. Accessed on July 9, 2002.
Pharmaceutical Research and Manufacturers of America (PhRMA). 2002 Survey: new medicines in development for older Americans. www.phrma.org. Accessed July 9, 2002.
Pharmaceutical Research and Manufacturers of America (PhRMA). Online clinical trials database, respiratory disorders, asthma. www.phrma.org. Accessed July 2, 2002.
Pharmaceutical Research and Manufacturers of America (PhRMA). New medicines in development for neurologic disorders. www.phrma.org. Accessed July 2, 2002.
Pharmaceutical Research and Manufacturers of America (PhRMA). Selected medicines in development for heart disease and stroke. January 2002. www.phrma.org. Accessed June 24, 2002.
Pharmaceutical Research and Manufacturers of America (PhRMA). Selected drugs in development for cancer. January 2002. www.phrma.org. Accessed June 24, 2002.
Quebec Prescription Drug Insurance Plan. List of medications. www.ramq.gouv.qc.ca/crc/eng/cit/assmed/cond.shtml. Accessed on July 9, 2002.
Sabatine MS, Jang I-K. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. American Journal of Medicine. 109, 224-237, 2000.
Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. Journal of the American Medical Association. 283(18), 2395-403, 2000.
Sliverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Journal of the American Medical Association. 284(10), 1247-55, September 2000.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine. 344(11), 783-792, 2001.
Swislocki AL, Siegel D. Renal effects of Angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes. American Journal Managed Care. 7(3), 283-295, 2001.
Szelenyi I. Asthma therapy in the new millennium. Inflammation Research. 51(6),273-282, 2002.
Tajima O. Mental health care in Japan: recognition and treatment of depression and anxiety disorders. Journal of Clinical Psychiatry. 62(suppl 13), 39-44, 2001.
Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. Journal of the American Medical Association. 280(17), 1490-1496, 1998.
Tobias JH, Flanagan AM, Scutt AM, Novel therapeutic targets in osteoporosis. Expert Opinion on Therapeutic Targets. 6(1),41-56, 2002.
Tufts Center for the Study of Drug Development. How new drugs move through the development and approval process. 2001. www.csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=4. Accessed June 28, 2002.
United Nations. World population aging: 1950-2050. United Nations. New York, NY. 2002.
United Press International. ‘Breakthrough’ diabetes drug tested. June 18, 2002. www.nlm.nih.gov/medlineplus/news/fullstory_8144.html. Accessed on June 24, 2002.
United States International Trade Commission. Pricing of Prescription Drugs. United States International Trade Commission. Publication 3333. December 2000.
University of Washington School of Medicine. OsteoEd website osteoed.org/cases/overview.html. Accessed on June 27, 2002.
Walker, M. Wilson, G. Waiting your turn: hospital waiting lists in Canada. Fraser Institute. Eleventh edition. September 2001.
Wall Street Journal. Cancer-gene drugs flourish, yielding hope, but no quick fix. May 16, 2002.
Weinstein JN. Pharmacogenomics – teaching old drugs new tricks. New England Journal of Medicine. 343(19), 1408-1409, 2000.
World Intellectual Property Organization (WIPO). Discussion paper. Policy Advisory Task Force Meeting. Beijing, China. May 22, 2002.